Published in final edited form as:

J Med Chem. 2012 September 13; 55(17): 7623–7635. doi:10.1021/jm3006355.

Identification of a Promising Drug Candidate for the Treatment of Type 2 Diabetes Based on a P2Y₁ Receptor Agonist ¶

Shir Yelovitch^{†,¶}, Haim M. Barr^{‡,¶}, Jean Camden[§], Gary A Weisman[§], Ela Shai[‡], David Varon[‡], and Bilha Fischer^{*,†}

[†]Department of Chemistry, Bar-Ilan University, Ramat-Gan 52900, Israel

[‡]BioLineRx Ltd., 23 Hillel Street, Jerusalem 91450, Israel

[§]Biochemistry Department, 540E Bond Life Sciences Center, University of Missouri, Columbia, Missouri 65211, United States

[‡]Department of Hematology, Hadassah University Hospital, Jerusalem 91120, Israel

Abstract

The activation by extracellular nucleotides of pancreatic P2Y receptors, particularly, the P2Y₁R subtype, increases insulin secretion. Therefore, we developed analogues of the P2Y₁R receptor agonist 2 MeS ADP, as potential antidiabetic drugs. Analogue 3A was found to be a potent P2Y₁R agonist ($EC_{50} = 0.038 \mu\text{M}$ vs $0.0025 \mu\text{M}$ for 2 MeS-ADP) showing no activity at P2Y_{2/14/6}Rs. Analogue 3A was stable at pH 1.4 ($t_{1/2} = 7.3$ h) and resistant to hydrolysis vs 2-MeS ADP by alkaline phosphatase ($t_{1/2} = 6$ vs 4.5 h), human e-NPPI (4% vs 16% hydrolysis after 20 min), and human blood serum (30% vs 50% hydrolysis after 24 h). Intravenous administration of 3A in naive rats decreased blood glucose from 155 mg/dL to normal values, ca. 87 mg/dL, unlike glibenclamide, leading to subnormal values (i.e., 63 mg/dL). Similar observations were made for

¶Patent pending.

© 2012 American Chemical Society

*Corresponding Author Fax: 972-3-6354907. Tel: 972 3 5318303. bilha.fischer@biu.ac.il.

Author Contributions

These authors contributed equally.

Notes

The authors declare no competing financial interest.

streptozotocin (STZ) treated and db⁺/db⁻ mouse models. Furthermore, 3A inhibits platelet aggregation *in vitro* and elongates bleeding time in mice (iv administration of 30 mg of 3A/kg), increasing bleeding time to 16 vs 9 min for Prasugrel. Oral administration of 30 mg/kg 3A to rats increased tail bleeding volume, similar to aspirin. These findings suggest that 3A may be an effective treatment for type 2 diabetes by reducing both blood glucose levels and platelet aggregation.

INTRODUCTION

Diabetes mellitus is a chronic, incurable metabolic disorder defined by a dysregulation of glucose homeostasis manifesting as hyperglycemia, abnormalities in lipid and protein metabolism, and the development of both acute and long-term complications.^{1,2} Type 2 diabetes is the most prevalent form of the disease, affecting approximately 95% of patients with diabetes. It is characterized by insulin resistance,³ relatively reduced insulin secretion,⁴ or both and is largely the result of excess body weight and physical inactivity.

According to the World Health Organization, type 2 diabetes affects over 170 million people worldwide. This number is expected to double by 2025. Effective glycemic control can lower the incidence of diabetic complications and reduce their severity. Thus, enhancement of insulin secretion in type 2 diabetes is a major therapeutic goal.

Approximately half of the patients with type 2 diabetes are treated with various oral agents that stimulate insulin secretion.^{5,6} Among insulin secretagogues, sulfonylureas are the major oral antidiabetic agents currently available. Sulfonylureas elicit insulin secretion by binding to K_{ATP} channels of pancreatic β -cells and inducing their closure.⁷ Since this effect of sulfonylureas is not glucose-dependent, the primary side effect is hypoglycemia⁸ due to stimulation of insulin secretion at low glucose concentrations. In addition, sulfonylureas have possible long-term adverse effects on the functions of pancreatic β -cells and the cardiovascular system.⁹

Adenine nucleotides (e.g., ATP and ADP) enhance glucose-induced insulin secretion by activating G protein-coupled P2Y receptors in pancreatic β -cells,^{10,11} which has been shown to increase the insulin response *in vivo*.¹² A variety of P2 receptor agonists have been shown to stimulate glucose-dependent insulin release in human pancreatic islets.¹³ Thus, P2Y receptor agonists show promise in the treatment of type 2 diabetes. ADP and its analogues induce glucose-dependent insulin secretion more potently than ATP and its analogues,^{14,15} suggesting a role for an ADP-preferring receptor, such as the P2Y₁R.

A role for P2Y₁R activation has been implicated in the maintenance of glucose homeostasis and insulin secretion in mice.¹⁶ Thus, the use of P2Y₁R-selective ligands may represent a novel and effective approach for regulating glucose homeostasis in type 2 diabetes. Indeed, we found that α -borano-2-MeS-ATP, analogue 1, *R_p*-isomer (Figure 1), is a potent and selective agonist of the P2Y₁R (EC₅₀ = 2.6 nM vs 0.2 μ M for ATP) in HEK 293 cells overexpressing the P2Y₁R.¹⁷ Furthermore, analogue 1A was shown to be a very potent glucose dependent insulin secretagogue in isolated rat pancreas at elevated blood glucose levels¹ and thus may minimize the risk of hypoglycemia seen with sulfonylureas. Analogue

IA increases insulin secretion up to 9 fold greater than basal secretion with an EC₅₀ of 28.1 nM.¹⁵ Moreover, analogue IA exhibited high stability at physiological and gastric pH at 37 °C, with half lives of 1395 and 5.9 h, respectively. Yet, analogue IA was hydrolyzed almost completely by alkaline phosphatase over 100 min at 37 °C.¹⁸

In this study, we attempted to develop an insulin secretagogue based on the structure of P2Y₁R agonists (i.e., ADP and 2-MeS-ADP) that is metabolically stable under physiological conditions. Since the most potent P2Y₁R agonists are ADP and its analogues, we chose to use the ADP(α -B) scaffold to synthesize potential drug candidates. The ADP(α -B) scaffold is expected to be resistant to enzymatic hydrolysis by alkaline phosphatase, eNPP1 (ecto-nucleotide pyrophosphatase, EC 3.1.4.1), or NTPDase (ecto-nucleoside triphosphate diphosphohydrolase, EC 3.6.1.5) because of the proximity of the borane moiety to the cleavage site of ADP between P α and P β . In addition, we synthesized analogues that incorporate a diadenosine polyphosphate scaffold, which has been shown to generate P2 receptor ligands with high enzymatic stability and receptor specificity.¹⁹ In an attempt to enhance agonist potency and selectivity for the P2Y₁R, as previously described,^{20,21} we incorporated methylthio groups at the adenine C2 positions of the analogues. Here, we describe the synthesis and characterization of analogues 2-4 (Figure 2), and their activities at the P2Y₁R vs the P2Y_{2/4/6}Rs. In addition, we report on the chemical stability of the analogues and their resistance to hydrolysis by alkaline phosphatase, human eNPP1, and enzymes in human blood serum. Furthermore, we demonstrate that analogue 3 is an effective modulator of blood glucose and insulin levels *in vivo* in both normal and diabetic mice and rats and also acts as an inhibitor of platelet aggregation.

RESULTS

Synthesis of Analogues 2 and 3

Since 2-MeS-ADP is among the most potent P2Y₁R agonists currently known, we chose 2-MeS-adenosine as the starting material for the preparation of 2-MeS-ADP(α -B), analogue 3. We synthesized 2-MeS-ADP(α -B), analogue 3 in a one-pot, five-step synthesis outlined in Scheme 1. In addition, to determine whether a 2-MeS substitution enhances agonist activity and enzymatic stability in comparison to ADP(α -B), analogue 2, the latter was also synthesized as described in Scheme 1.²² The use of phosphitylation and boronation reagents in the synthetic method depicted in Scheme 1 requires protected nucleosides. It has been shown that protection of the adenine N⁶-position is not required, but selectivity for the 5'-OH in the initial phosphitylation step is marginal if the 2'- and 3'-OH are not protected.²³ To minimize the number of synthetic steps, we chose a methoxymethylidene protecting group that is selective for 2',3'-hydroxyl groups, thus avoiding protection of the 5'-OH, and this protecting group remained throughout the entire synthesis. In the last step of the boronation reaction in Scheme 1, the protecting group was removed under mild conditions that do not affect the formed boranophosphate moiety or the N-glycosidic bond. Removal of the methoxymethylidene group involved a hydrolysis step at pH 2.3 and another at pH 9,^{24,25} at which point product 11 was stable. Furthermore, both of these steps were relatively rapid, lasting less than 4 h, compared with 24–48 h required for the removal of alternative acetate protecting groups. Methoxymethylidene-protected nucleoside 5 (Scheme 1) was treated with

2-chloro-4*H*-1,3,2-benzodioxaphosphorine-4-one in dry dioxane to form the activated phosphate intermediate 6, to which bis(tributylammonium) pyrophosphate salt was added at room temperature yielding the cyclic triphosphate intermediate 7, which underwent a subsequent boronation step to yield product 8. A slight excess of 2-chloro-4*H*-1,3,2-benzodioxaphosphorine-4-one (1.1 equiv) and pyrophosphate tributylammonium salt (1.5 equiv) was used to ensure the complete formation of intermediate 6 and possibly intermediate 7. Among borane complexes that react as Lewis acids, we selected borane-dimethylsulfide, a boronation reagent that is effective under mild conditions (i.e., for 15 min at room temperature). Coordination of the electron-deficient borane of borane-dimethylsulfide with cyclic trivalentphosphorous intermediate 7, a Lewis base, yielded intermediate 8. In the same pot, intermediate 8 was reacted with ethylenediamine at room temperature to form methoxymethylidene-protected 2-MeS-ADP(α -B) analogue 11. After purification of analogue 11 on an anion exchange column, the methoxymethylidene protective group was removed, as described above, to generate analogue 3 at a 40% yield after LC separation.

The identity and purity of analogue 3 were established by ^1H and ^{31}P NMR, ESI, and MALDI negative mass spectrometry and HPLC using two solvent systems. ^{31}P NMR spectra of analogue 3 showed a typical $\text{P}\alpha$ signal as a multiplet at about 84 ppm. ^1H NMR spectra showed borane hydrogen atoms as a very broad signal at about 0.3 ppm. Due to the chiral center at $\text{P}\alpha$, analogue 3 was obtained as a pair of diastereoisomers in a 1:1 ratio. In both ^1H and ^{31}P NMR spectra, there are slight differences between the chemical shifts for the two diastereoisomers.

^aReaction conditions: (a) DMF/pyridine/dioxane, salicylphosphochloridite, RT, 10 min; (b) $\text{P}_2\text{O}_7\text{H}_2 \cdot 2-(\text{Bu}_3\text{NH}^+)_2/\text{DMF}$, Bu_3N , RT, 10 min; (c) 2 M BH_3/SMe_2 in THF, RT, 15 min; (d) (1) $\text{NH}_2\text{CH}_2\text{CH}_2\text{NH}_2$, RT, 1 h; (2) dist H_2O , RT, 30 min; (e) (1) pH 2.3, RT, 3 h; (2) pH 9, RT, 45 min.

Determination of the Absolute Configuration of Analogue 3 Diastereoisomers

Analogue 3 diastereomers were efficiently separated by reverse-phase HPLC using 100 mM triethylammonium acetate (pH 7)/acetonitrile, with a 1–2 min difference in their retention times. The separated diastereomers were designated as diastereomer A and diastereomer B with the A isomer eluting before the B isomer.

The spectral characteristics of analogue **3A** and **3B** isomers were very similar except for changes in the chemical shifts of H8 and $\text{P}\alpha$ in ^1H and ^{31}P NMR spectra (H8 at 8.45 and 8.42 ppm and $\text{P}\alpha$ at 83.0 and 84.1 ppm for **3A** and **3B** isomers, respectively). Prior assignment of configurations for $\text{NDP}\alpha\text{S}$ and $\text{NDP}\alpha\text{Se}$ were S_p and R_p for these first and second eluting diastereomers, respectively.²⁶ Since the group priorities around $\text{P}\alpha$ for $\text{NDP}\alpha\text{S}$ and $\text{NDP}\alpha\text{Se}$ are opposite to those of $\text{NDP}\alpha\text{B}$ (Figure 3) and assuming that the same order of elution occurs with analogues **3A** and **3B** ($\text{NDP}\alpha\text{B}$) compared with $\text{NDP}\alpha\text{S}$ and $\text{NDP}\alpha\text{Se}$, the assignment of configuration for $\text{NDP}\alpha\text{B}$ is R_p and S_p for analogues **3A** and **3B**, respectively. This assignment of the absolute configuration for $\text{ADP}\alpha\text{B}$ is consistent with the opposite stereospecificity toward S_p and R_p selective enzymes.²⁷ The assignment of the absolute configuration for both diastereomers is further confirmed by ^1H NMR. A

difference in the chemical shift of H8 is observed between the two diastereoisomers, as shown in Table 1. The signal of H8 of the B isomer of analogue 3 in ^1H NMR spectra is more shielded than the signal of H8 of the A isomer due to the influence of the vicinal BH3 group on P α (8.45 vs 8.42 ppm). This small, although indicative, δ between H8 of A and B isomers may be explained in terms of the closer proximity to H8 of the negative charge on BH3 compared with O for the B isomer (Figure 3) and is due to the longer P-B bond (1.89 Å) compared with P-O (1.60 Å), in addition to the contribution of the B-H bond (1.25 Å).²⁸ Furthermore, the upfield shift of H8 of the B isomer may be due to an unconventional H-bond between the BH3 group and the relatively acidic H8²⁹ that is known to exist between borane-amines and acidic protons.³⁰ Such a preferential intramolecular H-bond results in the shielding of H8. Previous calculations²⁵ indicate that P α is much further away from H8 in the A isomer than in the B isomer. Thus, the Sp configuration can be attributed to analogue 3B and R_p to analogue 3A of 2-MeS-ADP(α -B).

Synthesis of Analogue 4

Dinucleoside polyphosphates are conventionally prepared via the activation of the 5' terminal phosphates of a nucleotide with carbonyl diimidazole (CDI),³¹ thereby forming a phosphoryl donor (P-donor) that reacts with a nonactivated nucleotide (i.e., phosphoryl acceptor (Pacceptor)). We attempted two different approaches to synthesize analogue 4. In the first approach, analogue 12 was activated with CDI to generate the P-donor and analogue 13 was the P-acceptor (Scheme 2). In the second approach, CDIactivated analogue 13 was the P-donor and analogue 12 was the P-acceptor. The activation of analogues 12 and 13 with CDI was monitored by TLC, which showed that analogue 12 reacted completely with CDI after 3 h, whereas the activation of analogue 13 was incomplete over this time period, likely due to the low nucleophilicity of the phosphate group in analogue 13. Therefore, we chose to synthesize analogue 4 by activating analogue 12 with CDI.

Briefly, the synthesis of analogue 4 involved the activation of the 2-MeS-AMP(Bu₃NH)₂⁺ salt with CDI in dry DMF at room temperature for 3 h, followed by the addition of the bis(Bu₄N)⁺ salt of 2-MeS-ADP(α -B) and MgCl₂. After 12 h at room temperature, analogue 4 was formed as the exclusive product at 80% yield after LC separation. Due to the chiral center at P α , analogue 4 was obtained as a pair of diastereoisomers in a 1:1 ratio. Each diastereoisomer exhibits a characteristic ^{31}P NMR spectrum showing three signals: 87 (m, P α -B), 10.5 (d, P α), and -21.5 (dd, P'') ppm.

Activity of Analogues 2.4 at the P2Y_{1/2/4/6} Receptors

The activities of analogues 2.4 were evaluated at the turkey P2Y₁ receptor expressed in human 1321N1 astrocytoma cells that are devoid of endogenous P2Y receptors.³² The order of potency of agonists for activation of the turkey P2Y₁-R was found to be identical to that observed for the human P2Y₁-R.³³ P2Y₁R activity was determined by monitoring increases in the intracellular calcium concentration, [Ca²⁺]_i, induced by the analogues (Figure 4).

ADP(α -B), analogue 2, activated the P2Y₁R with EC₅₀ values of 0.22 and 0.96 μM for isomers 2A and 2B, respectively. 2-MeS-ADP(α -B), isomers **3A** and **3B**, exhibited EC₅₀ values of 0.038 and 1.1 μM , respectively. Thus, substitution at C2 of ADP(α -B) by an

electron-donating 2-MeS group increased by 6-fold the agonist potency of the **3A** isomer at the P2Y₁R. 2-MeS-Adp3(α -B)-A-2-MeS, isomers 4A and 4B, had EC₅₀ values of 0.14 and 0.19 μ M at the P2Y₁R, respectively. Here, the contribution of the 2-MeS substitution to ligand activity can be demonstrated by comparing the EC₅₀ values of the analogue 4 isomers to those of Adp3(α -B)A isomers, which are 0.76 and 0.8 μ M, respectively.³⁴ In this case, the MeS substitution at C2 resulted in a 4.6-fold increase in potency, as well. All tested analogues are less potent agonists of the P2Y₁R than 2-MeSADP (EC₅₀ = 0.0025 μ M). Thus, the borane group reduces P2Y₁R activity by at least 15-fold. The activities of the diastereomers of analogue 4 at the P2Y₁R are only slightly different. For the NDP(α -B) analogues 2 and 3, it was found that the A isomers are ~4-30-fold more potent in increasing [Ca²⁺]_i than the corresponding B isomers. Apparently, the A isomers, Rp configuration (Figure 3), promote tighter receptor binding. These analogues were virtually ineffective agonists of the P2Y₂, P2Y₄, and P2Y₆ receptors (data not shown).

Resistance of Analogues 2–4 to Degradation by Alkaline Phosphatase

Alkaline phosphatase (AP) is a hydrolase that catalyzes the removal of a phosphate group from nucleotides to generate inorganic phosphate (Pi) and the corresponding alcohol. AP catalyzes the stepwise production of Pi by ATP hydrolysis to ADP and subsequently AMP.³⁵ In humans, AP is present in all tissues.³⁶

The hydrolysis rates of analogues 2–4 by AP were determined by measuring the change in the integrated HPLC peaks for each analogue over time. Results are given for the incubation of 0.5 mg of substrate in 32.5 μ L of Tris buffer containing 6.25 units of AP at 37 °C for 8 h. Samples were taken every 1 h. The enzyme was then deactivated by heating to 75 °C for 5 min. As a control, we used a sample that did not contain enzyme to ensure that the tested compounds were not degraded at 75 °C. The half-life of ADP, the endogenous ligand of the P2Y₁R, is 4 h under the above conditions, whereas the half-lives of ADP(α -B), 2A, 2-MeS-ADP, and 2-MeS-ADP(α -B), 3A, are 4.2, 4.5, and 6 h, respectively (Table 2). 2-MeSAdp3(α -B)-A-2-MeS (analogue 4) is completely resistant to hydrolysis by AP over this time course (Table 2), suggesting that it is not a substrate of the enzyme.

Resistance of Analogues 2.4 to Degradation by Human eNPP1

eNPP1 cleaves NDP into NMP and Pi and NpnN into NMP and Npn.¹ Because members of the eNPP family share an alkaline pH optimum, eNPP1 activity was measured at pH 8.5. Human eNPP1 (11 mg/mL) was added to incubation buffer at 37 °C and preincubated for 3 min, and the reaction was started by addition of 0.2 mM analogue 2, 3, or 4 and terminated after 20 min by addition of perchloric acid.³⁷ Parent compounds and degradation products were separated and quantified by HPLC. The concentrations were determined from the relative area under the absorbance peaks.

The percentage of analogue degraded over time was calculated vs control to take into consideration the eNPP1-independent degradation of the compounds due to perchloric acid addition at the end of the assay. The percentage of degradation was calculated from the AUC of the NMP peak after subtraction of the control.

Over a 20 min period, ADP was 25% degraded into AMP and Pi, whereas 2-MeS-ADP was only 16% degraded (Table 2). Replacing the P α oxygen atom with a borane group increased the analogue's stability. Under the same conditions, the A isomers of ADP(α -B) (analogue 2) and 2-MeS-ADP(α -B) (analogue 3) were only 5% and 4% degraded, respectively (Table 2). The A and B isomers of 2-MeS-Ad₃(α -B)-A-2-MeS (analogue 4) were 0% and 5% degraded, respectively (Table 2).

Resistance of Analogues 2–4 to Hydrolysis in Human Blood Serum

Nucleotides and their analogues undergo enzymatic degradation in physiological systems.³⁸ Blood serum contains nucleotide-hydrolyzing enzymes and, therefore, provides a good model system for assessing the metabolic stability of extracellular nucleotides.

The hydrolysis rates of analogues 2–4 in human blood serum prepared from whole blood of healthy volunteers were determined as follows: 40 mM analogue in deionized water, human blood serum (180 μ L), and RPMI-1640 medium (540 μ L) were incubated at 37 °C for 24 h. 39 Samples were taken every 1 h, and serum enzymes were inactivated by heating at 80°C for 30 min. As a control, analogues were incubated in the absence of blood serum, to determine the extent of heatdependent degradation. T_{1/2} values for degradation were determined by measuring the change in the integration of the HPLC peak for each analogue over time. ADP was hydrolyzed with a half-life of 2 h (Figure 5). ADP(α -B), the 2A isomer, was hydrolyzed with a similar half-life of 3.5 h (Table 2). The halflife of 2-MeS-ADP was found to be 23 h. The 3A isomer, 2-MeS-ADP(α -B), was highly stable under these conditions with only 40% degraded over 24 h and a half-life similar to 2-MeSADP (Figure 5 and Table 2). These results indicate that the borane moiety confers enzymatic stability in human serum for analogue 3A and the 2-MeS substitution is the main stabilizing factor.

Both A and B isomers of 2-MeS-Ad₃(α -B)-A-2-MeS (analogue 4) exhibited half-lives in human serum of 14 h (Table 2), indicating a 7-fold enhancement compared with the half-life of ADP.

Stability of Analogue 3 at Acidic pH

To explore the suitability of 2-MeS-ADP(α -B) as a drug candidate for oral administration, we evaluated its chemical stability at pH 1.4 at 37 °C, which mimics the acidity of gastric juice. The chemical stability was evaluated for a diastereoisomeric mixture of 2-MeS-ADP(α -B) trisodium salt in KCl/HCl buffer at pH 1.4 and was monitored by HPLC over 12 h. The hydrolysis rate was determined by measuring the change in the integration of the respective HPLC peaks with time to fit a pseudo-first-order reaction model. The hydrolysis rate constant for analogue 3A/ B was found to be $2 \times 10^{-5} \text{ s}^{-1}$ ($t_{1/2} = 7.3 \text{ h}$) (Figure 6).

Analogue 3A Decreases Blood Glucose Levels in Both Naïve and Diabetic Animals

Since the A isomer of 2-MeSADP(α -B) was found to be a potent and enzymatically stable P2Y₁R agonist, *in vivo* studies were performed to test the potential of analogue 3A administration as a treatment for type II diabetes. Initially, analogue 3A was evaluated for *in vivo* efficacy in the regulation of glucose homeostasis in rats and mice using an oral glucose

tolerance test (OGTT). Rats were studied only in the context of a cross-species proof of principle.

Blood glucose levels of overnight-fasted rats and mice rose quickly after oral administration of a glucose challenge. However, this increase in blood glucose levels was significantly reduced when rats were administered analogue 3A (30 mg/kg body weight, iv) or glibenclamide (1 mg/kg body weight), a sulfonylurea well-known as an insulin secretagogue. Glibenclamide is administered per os because it is necessary to allocate time for GI absorption and this is the acceptable means of administration in the clinic. Compared with saline administration, analogue 3A reduced the glucose load within 45 min from 155 to ca. 87 mg/dL, whereas glibenclamide reduced glucose levels to ca. 63 mg/dL, lower than the basal level (Figure 7A). The effect of analogue 3A on blood glucose levels was also tested at doses of 10 and 30 mg/kg body weight in mice with the higher dose being more effective at reducing the glucose load (Figure 7B). In contrast, analogue 3B is ineffective when administered at 30 mg/kg body weight (Figure 7C). Moreover, a mixture of analogues 3A and 3B, 30 mg/kg total, was less effective than analogue 3A alone (Figure 7C), suggesting that the diastereoisomers are not equipotent *in vivo* and that separation of the diastereoisomers before administration is preferable.

Being active in naïve animals, analogue 3A was also tested in two diabetic mouse models. The first model used is chemically induced diabetes, achieved by administration of streptozotocin (STZ), a naturally occurring chemical that is toxic to insulinproducing beta cells in the pancreas of mammals.⁴⁰ Mice were given 100 mg/mL STZ intraperitoneally (IP) for 14 days to induce a hyperglycemic response to a glucose challenge. The second diabetic mouse model used is a genetically diabetic mouse (db⁺/db⁻)⁴¹ that displays elevated basal glucose levels. Analogue 3A administered at 30 mg/kg was found to lower blood glucose levels to normal values in both models (Figures 8 and 9). The db⁺/db⁺ (homozygous) mice were not tested with analogue 3A, because preliminary studies indicate that they are not responsive to sulfonylureas (data not shown).

Analogue 3A Inhibits ADP-Induced Platelet Aggregation

Analogue 3A was found to be a potent P2Y₁R agonist. Besides lowering blood glucose levels, P2Y₁R agonists have been suggested to initiate platelet aggregation resulting in cardiovascular complications.⁴² Thus, the effect of analogue 3A on platelet aggregation was tested both *in vitro* (using human blood) and *in vivo* (using mice). Exposure of platelet-rich plasma (PRP) to analogue 3A does not cause platelet aggregation (data not shown), whereas ADP, the endogenous ligand of the P2Y₁R, (and the P2Y₁₂R) induces platelet aggregation (Figure 10) at low micromolar concentrations.⁴¹ However, analogue 3A at 0.3.10 μ M reduced ADP-induced platelet aggregation in human plasma by 3- and 8-fold, respectively (Figure 10).

The anti-platelet aggregation activity of analogue 3A is also effective *in vivo*. Normal mice were injected iv with analogue 3A prior to a tail-cut that produces bleeding, and bleeding time was measured. At a dose of 30 mg/kg body weight, analogue 3A prolonged tail bleeding time ~1.5-fold, compared with an active metabolite of clopidogrel (R-361015, Daiichi Sankyo; an antiplatelet aggregation agent and antagonist of the P2Y₁₂R⁴⁴) (Figure

11). Similar to the dose of analogue 3A that inhibits platelet aggregation, a dose of 30 mg/kg body weight of analogue 3A also is effective at lowering blood glucose levels (Figure 7), an important correlation, since diabetic patients frequently suffer from platelet hypersensitivity and cardiovascular disease. The anti-platelet aggregation activity of analogue 3A *in vivo* is also exhibited upon oral administration. An oral dose of 30 mg/kg body weight of analogue 3A administered 30 min before tail-cut increased both bleeding time and blood volume in rats, similar to aspirin (Figure 12). Since analogue 3A is a potent and selective P2Y₁R agonist and the anti-platelet aggregation activity of nucleotide analogues is often attributed to antagonism of the P2Y₁₂R,⁴⁴ it seems likely that the antiplatelet aggregation effect of analogue 3A is due to inhibition of P2Y₁₂R activity. Indeed, we found that analogue 3A displayed partial agonist activity at the P2Y₁₂R relative to the endogenous agonist ADP (Figure 13), thus acting as a P2Y₁₂R antagonist in the presence of ADP.

DISCUSSION

Sulfonylurea-based insulin secretagogues used for the treatment of type 2 diabetes suffer from various limitations, especially the risk of hypoglycemia. These limitations justify a search for novel insulin secretagogues acting via mechanisms other than the ATP-sensitive K⁺ channel, which is activated by sulfonylureas.

Analogue 3A Is a Highly Selective and Potent P2Y₁R Agonist

In the past years, we focused on designing modified nucleotides as drug candidates for the treatment of type 2 diabetes.^{15,28} The goal of these modifications to both the adenine (i.e., thioether at C2) and phosphate moieties (i.e., phosphorothioate or boranophosphate) was to improve the potency and selectivity of the nucleotides at the P2Y₁R activation of which mediates insulin secretion and to improve the chemical and metabolic stability of these agonists. A promising drug candidate was 2-methylthio-ATP(α -B), analogue 1A (Figure 1), which increased insulin secretion by 9-fold above the basal level with an EC₅₀ of 28 nM in isolated rat pancreas.¹⁵ Nevertheless, analogue 1A failed to induce insulin secretion *in vivo*, probably due to its rapid hydrolysis by alkaline phosphatase.³⁹ Therefore, our approach in the current study was to develop analogues with improved metabolic stability. Instead of ATP(α -B), we synthesized ADP(α -B), analogue 3 (Figure 2). This diphosphate scaffold was predicted to be enzymatically stable because of the proximity of the borane moiety to the cleavage site between P α and P" for alkaline phosphatase, eNPP1, or NTPDase. Furthermore, ADP and ADP analogues modified in the C-2 position are more potent ligands of the P2Y₁R than ATP.⁴⁵ In addition, we designed analogue 4 as a potential P2Y₁R agonist based on a diadenosine triphosphate (i.e., Ap₃A) scaffold (Figure 2), since dinucleoside polyphosphates are generally more stable and specific than endogenous nucleotide agonists of P2 receptors.⁴³ Shaver et al. reported that Ap₃A is a structural analogue of ADP.⁴⁶ Both analogues 3 and 4 activated the P2Y₁R. At the turkey P2Y₁R, analogue 3A and 3B isomers exhibited EC₅₀ values of 0.038 and 1.1 μ M, respectively, and analogue 4A and 4B isomers exhibited EC₅₀ values of 0.22 and 0.96 μ M, respectively (Figure 4), suggesting that these novel analogues have relatively high affinity for the P2Y₁R. Analogue 3A, being the most potent agonist, was selected as the lead candidate for further studies.

P2Y₁R Preferentially Binds the *R_p* Isomer of Analogue 3 Rather than the *S_p* Isomer

The diastereoselectivity of the P2Y₁R was demonstrated here very clearly, where the *R_p* isomer of analogue 3 (3A) was 30-fold more active than the *S_p* isomer of analogue 3 (3B). This finding is consistent with our observations in a previous study elucidating the origin of the P2Y₁Rs chiral discrimination.²⁵ In that study, involving experimental and computational ligand docking data, we found that the *Pa* pro-R oxygen atom of ATP is bound preferentially to the receptor, compared with the pro-S oxygen atom.

Thus, in the 2-MeS-ADP-*α*-B *S_p* isomer, the *Pa* R oxygen atom is not in the right position to bind the receptor tightly, resulting in a 30-fold higher EC₅₀ value than the *R_p* isomer. Previously, we hypothesized that the P2Y₁Rs chiral discrimination originates from the requirement that the nucleotide agonist interacts with Mg²⁺ ion within the receptor binding site.²⁵

Analogue 3A Is an Effective and Safe Drug Candidate for the Treatment of Type 2 Diabetes

STZ-induced diabetes in rodents is commonly used to evaluate efficacy of therapeutic agents. We have carefully calibrated this model to maintain a degree of pancreatic function to demonstrate that treatment with analogue 3A improves glucose metabolism in STZ-treated mice (Figure 8), presumably via enhanced insulin secretion. Taken together with the reduction in glucose levels following an OGTT in the db⁺/db⁻ mouse (Figure 9), analogue 3A has the potential to enhance glucose metabolism in diverse diabetes models. Analogue 3A is also an effective anti-platelet aggregation agent *in vitro* (Figure 10) and can extend bleeding time *in vivo* (Figures 11 and 12). Antithrombotic agents will usually prolong bleeding in animals; however further investigation is required to evaluate the therapeutic modality and efficacy of analogue 3A. The antiplatelet aggregation activity of analogue 3A may be attributed to potential antagonism of the P2Y₁₂R subtype.²⁸

SUMMARY AND CONCLUSIONS

We developed a novel, potent, selective, and stable P2Y₁R agonist based on an adenosine 5'-O-(*α*-borano)diphosphate scaffold (analogue 3). Analogue 3A is a highly potent P2Y₁R agonist with an EC₅₀ value of 38 nM. Furthermore, analogue 3A is chemically stable at gastric juice pH = 1.4 (at 37 °C) with a half-life of 7.3 h. In addition, analogue 3A proved to be resistant to hydrolysis by human eNPP1, alkaline phosphatase, and blood serum. Acute rodent models of diabetes were used to show the efficacy of analogue 3A in reducing a blood glucose load to basal levels in Naïve rats and mice and hyperglycemic mice, in contrast to reduction to subnormal levels with glibenclamide, a common therapeutic agent for type 2 diabetes. Analogue 3A also has anti-platelet aggregation activity, possibly due to antagonism of P2Y₁₂R activation by its endogenous ligand ADP. Analogue 3A is highly soluble in aqueous media and is absorbed orally, suggesting that analogue 3A is an attractive drug candidate for the treatment of type 2 diabetes.

EXPERIMENTAL SECTION

All air- and moisture-sensitive reactions were carried out in flamedried, argon-flushed, two-neck flasks sealed with rubber septa, and the reagents were introduced with a syringe.

Progress of reactions was monitored by TLC on precoated Merck silica gel plates (60F-254). Column chromatography was performed with Merck silica gel 60 (230-400 mesh). Visualization of reactants and products was accomplished with UV light. Compounds were characterized by nuclear magnetic resonance spectroscopy using Bruker DPX-300 or AC-200 spectrometers. ^1H NMR spectra were measured at 200 or 300 MHz. Nucleotides were characterized also by ^{31}P NMR in D_2O , using 85% H_3PO_4 as an external reference on a Bruker AC-200 spectrometer. Mass spectra were recorded on an AutoSpec-E FISION VG mass spectrometer using ESI (electron spray ionization) on a QTOF microinstrument (Waters, UK). Primary purification of the nucleotides was achieved on an LC (Isco UA-6) system using a column of Sephadex DEAE-A25 swollen in 1 M NaHCO_3 at 4°C for 1 day. The resin was washed with deionized water before use. The LC separation was monitored by UV detection at 280 nm. Final purification of the nucleotides and separation of the diastereomeric pairs was achieved on a HPLC (Elite Lachrom, Merck-Hitachi) system using a semipreparative reverse-phase column (Gemini $5\ \mu\text{C}18$ 110A, $250 \times 10\ \text{mm}^2$, $5\ \mu\text{m}$, Phenomenex, Torrance, USA). The purity of the nucleotides was evaluated by analytical reverse-phase column chromatography (Gemini $5\ \mu\text{C}18$ 110A, $150 \times 4.60\ \text{mm}^2$, $5\ \mu\text{m}$, Phenomenex, Torrance, USA) with two solvent systems: solvent system I (A) CH_3CN /(B) 100 mM triethylammonium acetate (TEAA), pH 7, and solvent system II (A) 0.01 M KH_2PO_4 , pH 4.5/(B) MeOH. For analytical purposes, a Gemini $5\ \mu\text{C}18$ 110A, $150 \times 4.60\ \text{mm}^2$, $5\ \mu\text{m}$ column was used. Conditions for LC and HPLC separations are described below. pH measurements were performed with an Orion microcombination pH electrode and a Hanna Instruments pH meter.

All commercial reagents were used without further purification unless otherwise noted. 2-Methylthioadenosine was synthesized from 2-thioadenosine, as described.⁴⁷ 2-Thioadenosine was obtained from adenosine in three steps, according to a previously reported procedure.⁴⁸ Analogue 2 was synthesized according to the literature.⁴⁹ For preparation of human blood serum, whole blood taken from a healthy volunteer was obtained from a blood bank (Tel-Hashomer Hospital, Israel). Blood was stored for 12 h at 4°C and centrifuged in plastic tubes at 1500g for 15 min at RT. The serum was separated and stored at -80°C .

2-Methylthioadenosine 5'-O-(γ -Borano)diphosphate (Analogue 3)

2-Methylthio-(2',3'-O-methoxymethylidene) adenosine (253 mg, 0.25 mmol) was dissolved in DMF (1.5 mL)/pyridine (1.25 mmol, 5 equiv). A freshly prepared solution of salicylphosphochloridite (0.275 mmol, 1.1 equiv) in freshly distilled dioxane was then transferred to the flask. After stirring for 10 min, a freshly prepared 1 M solution of bis(tri-*n*-butylammonium) pyrophosphate (0.375 mmol, 1.5 equiv) in DMF and tri-*n*-butylamine (1 mmol, 4 equiv) were simultaneously added. Precipitation occurred immediately after the addition of the reagents, but the precipitate disappeared with further stirring. A 2 M solution of $\text{BH}_3/\text{Me}_2\text{S}$ in THF (2 mmol, 8 equiv) was added, and the mixture was stirred for 15 min. Ethylenediamine (1.25 mmol, 5 equiv) was then added. A white precipitate was immediately formed. After stirring for 60 min, 1 mL of deionized water was added, and the white precipitate gradually dissolved. After 10 min, the reaction mixture was evaporated and then diluted with deionized water and washed twice with ethyl ether. The aqueous layer was

freeze-dried, and the semisolid obtained was chromatographed on an activated Sephadex DEAE-A25 column. The resin was washed with deionized water and loaded with the crude reaction residue dissolved in a minimal volume of water. The separation was monitored by UV at 280 nm. A buffer gradient of 400 mL of water to 400 mL of 0.4 M NH_4HCO_3 was used. The relevant fraction was collected and freeze-dried three times until a constant weight was obtained to yield the protected analogue 11 as a white solid. The methoxymethylidene protecting group was removed by acidic hydrolysis (10% HCl solution was added until pH 2.3 was obtained). After 3 h at room temperature, the pH was rapidly raised to 9 by the addition of NH_4OH (pH 11), and the solution was kept at room temperature for 40 min. Analogue 3 was obtained according to the above procedure at 45% yield (274 mg). Final purification and separation of diastereoisomers of analogue 3 were achieved on a semipreparative HPLC column with isocratic elution (B/A, 88:12) with flow rate of 5 mL/min. Fractions containing the same isomer (similar retention time) were freeze-dried. The triethylammonium counterions were exchanged for Na^+ by passing the pure diastereoisomers through a Sephadex-CM C-25 column.

Characterization of 2-Methylthioadenosine 5'-O-(β - Borano)diphosphate, A Isomer (Analogue 3A)

δ 14 min. ^1H NMR (200 MHz): $\sim$ 8.45 (s, H-8, ^1H), 5.99 (d, $J = 5.3$ Hz, H-1', ^1H), 4.47 (dd, $J = 3.8, 4.9$ Hz, H-3', ^1H), 4.24 (m, H-4', ^1H), 4.12 (m, H-5', 2H), 2.59 (s, S-CH₃, 3H), 0.47 (m, BH₃, 3H) ppm. ^{31}P NMR (200 MHz): $\sim$ -83 (m, P α -BH₃), -6.5 (d, P β) ppm. HR MALDI (negative): calculated for $\text{C}_{11}\text{H}_{19}\text{BN}_5\text{O}_9\text{P}_2\text{S}$ 470.134, found 470.139. Purity data obtained on an analytical column: retention time 3.53 min (97% purity) using solvent system I B/A 88:12 with a flow rate of 1 mL/min; retention time 2.15 min (97.5% purity) using solvent system II A/B 5:95 with a flow rate of 1 mL/min. Characterization of 2-Methylthioadenosine 5'-O-(β - Borano)diphosphate, B Isomer (Analogue 3B). Rt 16 min. ^1H NMR (200 MHz): $\sim$ 8.42 (s, H-8, ^1H), 5.99 (d, $J = 5.6$ Hz, H-1', ^1H), 4.39 (dd, $J = 5, 5.6$ Hz, H-3', ^1H), 4.25 (m, H-4', ^1H), 4.12 (m, H-5', 2H), 2.59 (2s, S-CH₃, 3H), 0.47 (m, BH₃, 3H) ppm. ^{31}P NMR (200 MHz): $\sim$ -84.1 (m, P α -BH₃), -6.8 (d, P'') ppm. Purity data obtained on an analytical column: retention time 4.73 min (97% purity) using solvent system I with a flow rate of 1 mL/min; retention time 3.15 min (98% purity) using solvent system II with a flow rate of 1 mL/min.

P1-Borano P1,P3-5'-Di-2-methylthioadenosine 5'-Triphosphate (Analogue 4)

2-MeS-AMP(Bu_3NH^+)₂ (79 mg, 0.184 mmol) was dissolved in dry DMF (2 mL), and CDI (163.7 mg, 0.92 mmol) was added. The resulting solution was stirred at room temperature for 3 h. Dry MeOH (80 μL , 0.92 mmol) was added. After 8 min, 2-MeS-ADP(α -B) (Bu_3NH^+)₂ (96 mg, 0.184 mmol) in dry DMF (2 mL) and MgCl_2 (4 equiv) were added. The resulting solution was stirred at room temperature overnight. The semisolid obtained after evaporation of the solvent was chromatographed on a Sephadex DEAE-A25 column. A buffer gradient of water (700 mL) to 0.5 M NH_4HCO_3 (700 mL) was applied. The relevant fractions were pooled and freeze-dried to yield a white solid. Final purification and separation of diastereoisomers of analogue 4 were achieved on a semipreparative HPLC column with isocratic elution using solvent system I B/A 88:12 with flow rate of 5 mL/min. Fractions containing the same isomer (similar retention time) were freeze-dried. The

triethylammonium counterions were exchanged for Na⁺ by passing the pure diastereoisomers through a Sephadex-CM C-25 column.

P¹-Borano P¹,P³-5'-Di-2-methylthioadenosine 5'-Triphosphate, A Isomer (Analogue 4A)

R_t 24.91 min. ¹H NMR (200 MHz): ~ 8.45 (s, H-8, ¹H), 5.99 (d, J = 5.3 Hz, H-1', ¹H), 4.47 (dd, J = 3.8, 4.9 Hz, H-3', ¹H), 4.24 (m, H-4', ¹H), 4.12 (m, H-5', 2H), 2.59 (2S, S.CH₃, 3H), 0.47 (m, BH₃, 3H) ppm. ³¹P NMR (D₂O, 81 MHz, pH 7): ~ 84 (m, P α , 1P), .11.5 (d, P α , 1P), .23 (dd, P'', 1P) ppm. HR MALDI (negative): calculated for C₂₂H₃₃BN₁₀O₁₈P₄S₂ 924.134, found 924.136. Purity data obtained on an analytical column: retention time 4.52 min (96% purity) using solvent system I with a flow rate of 1 mL/min; retention time 3.15 min (97% purity) using solvent system II with a flow rate of 1 mL/min.

P¹-Borano P¹,P³-5'-Di-2-methylthioadenosine 5'-Triphosphate, B Isomer (Analogue 4B)

R_t 29.15 min. ¹H NMR (200 MHz): ~ 8.42 (s, H-8, ¹H), 5.99 (d, J = 5.6 Hz, H-1', ¹H), 4.39 (dd, J = 5, 5.6 Hz, H-3', ¹H), 4.25 (m, H-4', ¹H), 4.12 (m, H-5', 2H), 2.59 (2S, S.CH₃, 3H), 0.47 (m, BH₃, 3H) ppm. ³¹P NMR (D₂O, 81 MHz, pH 7): δ 84 (m, P α , 1P), .11 (d, P α , 1P), -22.5 (dd, P'', 1P) ppm. Purity data obtained on an analytical column: retention time 5.62 min (96% purity) using solvent system I B/A 88:12 with a flow rate of 1 mL/min; retention time 4.25 min (96.5% purity) using solvent system II A/B 5:95 with a flow rate of 1 mL/min.

Intracellular Calcium Measurements

Human 1321N1 astrocytoma cells stably expressing the turkey P2Y₁ receptor were grown in Dulbecco's modified Eagle's medium containing 5% (v/v) fetal bovine serum, 100 units/mL penicillin, 100 μ g/mL streptomycin, and 500 μ g/mL Geneticin (G-418; Life Technologies, Inc.). Changes in the intracellular free calcium concentration, [Ca²⁺]_i, were detected by dual excitation spectrofluorometric analysis of cell suspensions loaded with fura-2, as described previously.⁵⁰ Cells were treated with the indicated nucleotide or analogue at 37 °C in 10 mM Hepes-buffered saline (pH 7.4) containing 1 mM CaCl₂ and 1 mM MgCl₂, and the maximal increase in [Ca²⁺]_i was determined at various nucleotide or analogue concentrations to calculate the EC₅₀. Concentration-response data were analyzed with the Prism curve fitting program (GraphPAD software, San Diego, CA). Three experiments were conducted on separate days.

Evaluation of the Stability of Analogues 2.4 with Human eNPP1

Human eNPP1 activity was measured at 37 °C in 1 mL of the following incubation medium: (in mM) 1 CaCl₂, 200 NaCl, 10 KCl, and 100 Tris, pH 8.5 (Sigma-Aldrich). Then, 0.1 mL of human eNPP1 enzyme preparation³⁷ (11.2 mg/mL, 6 μ L) was added to the reaction mixture, and the mixture was preincubated for 3 min at 37 °C. The reaction was initiated by addition of 0.5 mL of 0.2 mM substrate. The reaction was stopped after 20 min by transferring a 0.3 mL aliquot of the reaction mixture to 0.375 mL of ice-cold 1 M perchloric acid. The samples were centrifuged for 5 min at 10000g. Supernatants were neutralized with 1 M KOH at 4 °C and centrifuged for 5 min at 10000g. An aliquot of the supernatant (0.2 mL) was analyzed by HPLC to monitor the increase in NMP levels. The percentage of

substrate hydrolyzed in 20 min corresponds to the average of results from two experiments performed in triplicate.

Evaluation of the Resistance of Analogues 2-4 to Hydrolysis by Alkaline Phosphatase

Alkaline phosphatase (AP) activity was determined by the release of p-nitrophenol from p-nitrophenyl phosphate measured by a UV-vis spectrophotometer at 405 nm.⁵¹ Relative hydrolysis and resistance to hydrolysis by AP were determined for substrates at 37 °C. A solution of 0.2 mg of analogue in 77.5 μ L of deionized water, 0.1 M Tris-HCl, and 0.1 M MgCl₂ containing calf intestine alkaline phosphatase (Fermentas Inc., Glen Burnie, MD; 10 units/ μ L, 1.25 μ L, 12.5 units) was incubated at 37 °C. The final pH was 9.8. A sample was taken every 1 h for 8 h. The reaction was stopped by incubation of the sample at 80 °C for 15 min. Each sample was applied to an activated Starta X-AW weak anion exchange cartridge, and the resulting eluate was freeze-dried. Each cartridge was washed with H₂O (1 mL) and MeOH/H₂O (1:1, 1 mL), and the sample was eluted with NH₄OH/MeOH/H₂O (2:25:73, 1 mL), and freeze-dried. The resulting residue was analyzed by HPLC on a Gemini analytical column (5 μ C-18 110A; 150 nm $\times$ 4.60 nm). The hydrolysis rates of analogues by alkaline phosphatase were determined by measuring the change in the integration of the HPLC peaks for each analogue over time.

Evaluation of the Stability of Analogues 2-4 in Human Blood Serum

For preparation of human blood serum, whole blood taken from a healthy volunteer was obtained from a blood bank (Tel- Hashomer Hospital, Israel). Blood was stored for 12 h at 4 °C and centrifuged in plastic tubes at 1500g for 15 min at RT. The serum was separated and stored at -80 °C. The assay mixture containing 40 mM analogue in deionized water (4.5 μ L), human blood serum (180 μ L), and RPMI-1640 medium (540 μ L)³⁹ was incubated at 37 °C for 0-24 h, and aliquots were withdrawn at 0.5-12 h intervals. Each sample was then heated to 80 °C for 30 min, treated with CM Sephadex-CM C-25 (1-2 mg), stirred for 2 h using a magnetic stirrer, and centrifuged for 6 min (17000g), and the aqueous layer was collected and extracted with chloroform (2 $\times$ 500 μ L). The aqueous layer was freeze-dried and then dissolved in 100 μ L of deionized water. Samples were loaded onto an activated Starta X-AW weak anion exchange cartridge, washed with H₂O (1 mL) and MeOH/H₂O (1:1, 1 mL), eluted with NH₄OH/MeOH/H₂O (2:25:73, 1 mL), and freeze-dried. The resulting residue was analyzed by HPLC on a Gemini analytical column (5 μ C-18 110A; 150 nm $\times$ 4.60 nm) at a flow rate of 1 mL/ min. The hydrolysis rates of analogues in human blood serum were determined by measuring the change in the integration of the HPLC peaks for each analogue over time.

Evaluation of the Chemical Stability at Acidic pH of 2- Methylthioadenosine 5'-O-(α -Borano)diphosphate (Analogue 3)

2-Methylthioadenosine 5'-O-(α -borano)diphosphate (1.5 mg) was dissolved in 0.2 M HCl/KCl buffer (0.8 mL), and the final pH was adjusted to 1.4 using 0.2 M HCl. The reaction continued at 37 °C for 24 h with samples taken at 1 h intervals. The stability of 2-methylthioadenosine 5'-O-(α -borano)diphosphate was evaluated by HPLC to monitor degradation products using a Gemini analytical column (5 μ C-18 110A; 150 nm $\times$ 4.60 nm)

and the elution system TEAA/acetonitrile (88:12) at a flow rate of 1 mL/min. The hydrolysis rate of analogue 3 was determined by measuring the change in the integration of the respective HPLC peak with time.

***in vivo* Study**

Naïve Animals. Studies were performed by Vetgenerics Ltd. (Rehovot, Israel). Wister Han male rats and outbred mice (CD-1 mice, a trademark of Charles River Laboratory) were supplied by Harlan Laboratories (Israel). Rats and mice were acclimatized for 6 days prior to commencement of the study and inspected daily for health and welfare throughout the study. For rat studies, animals were weighed, and those most uniform in weight were surgically cannulated, as described below. Cannulated rats were examined for approximately 48 h following surgery to ensure recovery.

Surgical Cannulation Procedure—Rats and mice were anesthetized with 2.5% isoflurane and 97.5% dry air inhalation. Anesthetized rats were secured in the supine position and a 2 cm midline neck incision was fashioned to access the jugular vein and carotid artery. The latter experiment attempted to obtain large amounts of blood for more pharmacodynamic/pharmacokinetic data, but it was very traumatic and labor intensive, so we abandoned this approach and focused on less invasive studies afterward. P52 cannula was surgically inserted and fixed in the jugular vein and flushed with 0.3.0.5 mL of 5% (v/v) heparinized saline after cannulation and also immediately after each blood collection.

Oral Glucose Tolerance Test (OGTT)—The function of each cannula was checked in the morning of each experiment. Overnight fasting rats and mice were weighed, and peripheral tail vein blood glucose levels were measured with a glucometer (Abbott Glucometer FreeStyle or FreeStyle Lite), and animals with similar weights and blood glucose levels were assigned to the same group. Rats were left untouched in individual cages for approximately 2 h; mice were housed in treatment groups. Glibenclamide (1 mg/kg body weight) was administered orally by gavage at $t = .30$ min and then a glucose challenge of 2 g/kg body weight in a volume of 3 mL/kg body weight was orally administered to each animal at $t = 0$ min. Administration of analogue 3A or saline control to animals (5 per group) was performed at $t = 10$ min. Analogue 3A or saline was injected intravenously to both rats and mice via an iv catheter in volumes of 1 mL saline/kg body weight. Blood glucose levels were measured immediately following tail-vein puncture by placing a blood droplet on a glucometer stick inserted into the glucometer.

STZ-Induced Diabetic Mice—Studies were performed by Medicilon (Shanghai, China). Male ICR mice were supplied by Shanghai SINO British SIPPR/BK Lab Animal Ltd. (Shanghai, China). Environmental controls for animal rooms were set to maintain a temperature of 18.25 °C, humidity of 30.70%, and a 12 h light/12 h dark cycle. Mice were acclimatized for at least 3 days and then selected for the study based on overall good health and acclimation to caging.

Mice were housed 5 per cage. After 4.5 days of acclimatization, mice were randomly selected and treated with STZ (100 mg/kg body weight, IP) after 4 h of fasting. These mice

were supplied with 10% glucose water overnight to avoid sudden hypoglycemia postinjection. Control mice were given normal saline. Blood glucose levels and body weights of each mouse were measured on days 4 and 8 post-STZ treatment.

On day 10, the basal blood glucose levels and body weights of each mouse were measured after overnight fasting (about 16 h), 30 min before glucose challenge. STZ-treated mice were grouped according to basal glucose levels. Saline-treated mice were used as the control group. Blood glucose levels of each mouse were evaluated again at 15 min before glucose challenge after dosing with vehicle or 12 mg/kg body weight glibenclamide. Then (0 min time point), an oral dose of 1 g/kg body weight of D-glucose was given to each mouse at 10 mL/kg body weight, and the blood glucose level was measured at 15, 30, 60, and 120 min post-glucose challenge. Three doses of analogue 3A, either 30, 15, or 7.5 mg/kg body weight, were administered iv, 10 min after glucose administration.

Measurement of Blood Glucose Levels—Monitoring glucose levels in mouse blood was achieved using a OneTouch Ultra System (including glucose meter and test strips) from LifeScan Inc. (Milpitas, California, USA). Glucose levels were determined directly in a drop of fresh blood, according to MMPI standard operating procedures for measuring glucose levels in mouse blood.

Diabetic db⁺/db⁻ Mice—Studies were performed by ChemPartner (Shanghai, China). Male db⁺/db⁻ mice at 8 weeks of age were randomly assigned into groups according to body weight and blood glucose levels. Mice were fasted overnight and an OGTT was performed at -30, 0, 15, 30, 60, and 120 min, where 0 min is immediately before glucose administration. Glucose solution at 2 g/kg body weight was administered by oral gavage. Fifteen minutes before glucose administration, glibenclamide (2 mg/mL in cremophor/EtOH/saline 10:10:80%) was administered by gavage at 10 mL/kg body weight or 20 mg/kg body weight. Blood glucose levels were measured as described above.

Platelet Aggregation—Effects of analogues on platelet aggregation were determined as described in ref 52. PRP (platelet-rich plasma) was produced by centrifuging normal human plasma at 4400g for 30 s. PRP (225 μ L) was incubated for 15 min at 37 °C before inducing aggregation with ADP (25 μ L, 10 μ M; DiaAdin, DiaMed, Cressier, Switzerland), and platelet aggregation was determined after 6 min using the PAP-8E platelet aggregation profiler (BioData, Horsham, PA). The positive control was 10 μ M prasugrel metabolite.⁵³

Tail-Bleed Assay—Balb/c mice or Lewis rats were anesthetized and then analogues (30, 3, 0.3 mg/kg, mice; 30 mg/kg, rats) or saline were administered intravenously or orally. Aspirin (10 mg/kg body weight) was used as a control in rat experiments. Five minutes later, 2 mm was cut from the tip of the tail using a scalpel, and the tail was placed vertically in a test tube filled with saline. The time to first arrest of bleeding (*no* bleeding for 20 s) was determined. To determine the volume of blood collected, tubes were spun at 600g briefly, and the blood volume was determined visually and compared with known calibrated volumes.

ABBREVIATIONS USED

ADP	adenosine 5'diphosphate
ATP	adenosine 5'triphosphate
AUC	area under the curve
GPCR	G protein coupled receptor
HRMS	high resolution mass spectrometry
LC	liquid chromatography
NMP	nucleoside 5'monophosphate
eNPPs	ecto nucleotide pyrophosphatases
P2R	P2 receptor

REFERENCES

- (1). Adeghate, E. Archives of Physiology and Biochemistry. Vol. 109. Swets & Zeitlinger B.V.; Lisse, Netherlands: 2001. Special Issue on Diabetes Mellitus and its Complications: From Molecular Biology to Clinical Medicine; p. 96
- (2). Stefek, M. Advances in Molecular Mechanisms and Pharmacology of Diabetic Complications. Transworld Research Network; Kerala, India: 2010. p. 341
- (3). Hegarty BD, Turner N, Cooney GJ, Kraegen EW. Insulin resistance and fuel homeostasis: The role of AMP-activated protein kinase. *Acta Physiol.* 2009; 196:129–145.
- (4). Scheen AJ, Castillo MJ, Lefebvre PJ. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulindependent diabetes. *Acta Clin. Belg.* 1993; 48:259–268. [PubMed: 8212978]
- (5). U.K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet.* 1998; 352:837–853. [PubMed: 9742976]
- (6). Ishida H. Mechanism of action of antidiabetic sulfonylureas. *Diabetes Front.* 1999; 10:99–104.
- (7). Lebovitz, H. Oral Antidiabetic Agents. Lea and Febiger; Philadelphia, PA: 1994. p. 508-529.
- (8). Green JB, Feinglos MN. Are sulfonylureas passe? *Curr. Diabetes Rep.* 2006; 6:373–377.
- (9). Selvin E, Bolen S, Yeh H-C, Wiley C, Wilson Lisa M, Marinopoulos Spyridon S, Feldman L, Vassy J, Wilson R, Bass Eric B, Brancati Frederick L. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. *Arch. Intern. Med.* 2008; 168:2070–2080. [PubMed: 18955635]
- (10). Loubatieres-Mariani MM, Chapal J, Lignon F, Valette G. Structural specificity of nucleotides for insulin secretory action from the isolated perfused rat pancreas. *Eur. J. Pharmacol.* 1979; 59:277–286. [PubMed: 393523]
- (11). Chapal J, Loubatieres-Mariani MM. Effects of phosphatemoified adenine nucleotide analogs on insulin secretion from perfused rat pancreas. *Br. J. Pharmacol.* 1981; 73:105–110. [PubMed: 7025947]
- (12). Hillaire-Buys D, Bertrand G, Chapal J, Puech R, Ribes G, Loubatieres-Mariani MM. Stimulation of insulin secretion and improvement of glucose tolerance in rat and dog by the P2y purinoceptor agonist, adenosine-5'-O-(2-thiodiphosphate). *Br. J. Pharmacol.* 1993; 109:183–187. [PubMed: 8495239]
- (13). Fernandez-Alvarez J, Hillaire-Buys D, Loubatieres-Mariani MM, Gomis R, Petit P. P2 receptor agonists stimulate insulin release from human pancreatic islets. *Pancreas.* 2001; 22:69–71. [PubMed: 11138974]

- (14). Chapal J, Hillaire-Buys D, Bertrand G, Pujalte D, Petit P, Loubatieres-Mariani MM. Comparative effects of adenosine-5'- triphosphate and related analogs on insulin secretion from the rat pancreas. *Fundam. Clin. Pharmacol.* 1997; 11:537–545. [PubMed: 9444521]
- (15). Farret A, Filhol R, Linck N, Manteghetti M, Vignon J, Gross R, Petit P. P2Y receptor mediated modulation of insulin release by a novel generation of 2-substituted-5'-O-(1-boranotriphosphate)-adenosine analogues. *Pharm. Res.* 2006; 23:2665–2671. [PubMed: 17048117]
- (16). Leon C, Freund M, Latchoumanin O, Farret A, Petit P, Cazenave J-P, Gachet C. The P2Y1 receptor is involved in the maintenance of glucose homeostasis and in insulin secretion in mice. *Purinergic Signalling.* 2005; 1:145–151. [PubMed: 18404499]
- (17). Nahum V, Zuendorf G, Levesque SA, Beaudoin AR, Reiser G, Fischer B. Adenosine 5'-O-(1-boranotriphosphate) derivatives as novel P2Y1 receptor agonists. *J. Med. Chem.* 2002; 45:5384–5396. [PubMed: 12431066]
- (18). Eliahu SE, Camden J, Lecka J, Weisman GA, Seigny J, Gelinas S, Fischer B. Identification of hydrolytically stable and selective P2Y1 receptor agonists. *Eur. J. Med. Chem.* 2009; 44:1525–1536. [PubMed: 18760862]
- (19). Hoyle CHV, Hilderman RH, Pintor JJ, Schluter H, King BF. Diadenosine polyphosphates as extracellular signal molecules. *Drug Dev. Res.* 2001; 52:260–273.
- (20). Fischer B, Boyer JL, Hoyle CHV, Ziganshin AU, Brizzolara AL, Knight GE, Zimmet J, Burnstock G, Harden TK, Jacobson KA. Identification of potent, selective P2Y-purinoreceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate. *J. Med. Chem.* 1993; 36:3937–3946. [PubMed: 8254622]
- (21). Halbfinger E, Major DT, Ritzmann M, Ubl J, Reiser G, Boyer JL, Harden KT, Fischer B. Molecular recognition of modified adenine nucleotides by the P2Y1-receptor. 1. A synthetic, biochemical, and NMR approach. *J. Med. Chem.* 1999; 42:5325–5337. [PubMed: 10639276]
- (22). Li P, Sergueeva ZA, Dobrikov M, Shaw BR. Nucleoside and oligonucleoside boranophosphates: Chemistry and properties. *Chem. Rev.* 2007; 107:4746–4796. [PubMed: 17967037]
- (23). Burgess K, Cook D. Syntheses of nucleoside triphosphates. *Chem. Rev.* 2000; 100:2047–2059. [PubMed: 11749283]
- (24). Griffin BE, Jarman M, Reese CB, Sulston JE. The synthesis of oligoribonucleotides. II. Methoxymethylidene derivatives of ribonucleosides and 5'-ribonucleotides. *Tetrahedron.* 1967; 23:2301–313. [PubMed: 6044199]
- (25). Major DT, Nahum V, Wang Y, Reiser G, Fischer B. Molecular recognition in purinergic receptors. 2. Diastereoselectivity of the h-P2Y1-receptor. *J. Med. Chem.* 2004; 47:4405–4416. [PubMed: 15317453]
- (26). Li P, Shaw BR. Convenient synthesis of nucleoside borane diphosphate analogues: Deoxy- and ribonucleoside 5'-P#-boranodiphosphates. *J. Org. Chem.* 2004; 69:7051–7057. [PubMed: 15471452]
- (27). Krishnan P, Fu Q, Lam W, Liou J-Y, Dutschman G, Cheng Y-C. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: Selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. *J. Biol. Chem.* 2002; 277:5453–5459. [PubMed: 11741981]
- (28). Nahum V, Fischer B. Boranophosphate salts as an excellent mimic of phosphate salts: Preparation, characterization, and properties. *Eur. J. Inorg. Chem.* 2004:4124–4131.
- (29). Srivastava, PC.; Robins, RK.; Meyer, RB, Jr.. Chemistry of nucleosides and nucleotides. Townsend, LB., editor. Vol. 1. Plenum Press; New York: 1988.
- (30). Fujii A, Patwari GN, Ebata T, Mikami N. Vibrational spectroscopic evidence of unconventional hydrogen bonds. *Int. J. Mass Spectrom.* 2002; 220:289–312.
- (31). Zatorski A, Goldstein BM, Colby TD, Jones JP, Pankiewicz KW. Potent inhibitors of human inosine monophosphate dehydrogenase type II. Fluorine-substituted analogs of thiazole-4-carboxamide adenine dinucleotide. *J. Med. Chem.* 1995; 38:1098–1105. [PubMed: 7707313]
- (32). Parr CE, Sullivan DM, Paradiso AM, Lazarowski ER, Burch LH, Olsen JC, Erb L, Weisman GA, Boucher RC, Turner JT. Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. *Proc. Natl. Acad. Sci. U.S.A.* 1994; 91:3275–3279. [PubMed: 8159738]

- (33). Schachter JB, Li Q, Boyer JL, Nicholas RA, Harden TK. Second messenger cascade specificity and pharmacological selectivity of the human P2Y₁-purinoceptor. *Br. J. Pharmacol.* 1996; 118:167–173. [PubMed: 8733591]
- (34). Yelovitch S, Camden J, Weisman GA, Fischer B. Boranophosphate isoster controls P2Y receptor subtype selectivity and metabolic stability of dinucleoside polyphosphate analogues. *J. Med. Chem.* 2012; 55:437–448. [PubMed: 22107038]
- (35). Moss DW, Walli AK. Intermediates in the hydrolysis of ATP by human alkaline phosphatase. *Biochim. Biophys. Acta, Enzymol.* 1969; 191:476–477.
- (36). Harada M, Udagawa N, Fukasawa K, Hiraoka BY, Mogi M. Inorganic pyrophosphatase activity of purified bovine pulp alkaline phosphatase at physiological pH. *J. Dent. Res.* 1986; 65:125–127. [PubMed: 3003174]
- (37). Belli SI, Goding JW. Biochemical characterization of human PC-1, an enzyme possessing alkaline phosphodiesterase I and nucleotide pyrophosphatase activities. *Eur. J. Biochem.* 1994; 226:433–443. [PubMed: 8001561]
- (38). Gendaszewska-Darmach E, Maszewska M, Zaklos M, Koziolkiewicz M. Degradation of extracellular nucleotides and their analogs in HeLa and HUVEC cell cultures. *Acta Biochim. Pol.* 2003; 50:973–984. [PubMed: 14739990]
- (39). Eliahu S, Barr HM, Camden J, Weisman GA, Fischer B. A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold(1). *J. Med. Chem.* 2010; 53:2472–2481. [PubMed: 20175517]
- (40). Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. *Diabetologia.* 2008; 51:216–226. [PubMed: 18087688]
- (41). Chung WK, Belfi K, Chua M, Wiley J, Mackintosh R, Nicolson M, Boozer CN, Leibel RL. Heterozygosity for Lepob or Leprdb affects body composition and leptin homeostasis in adult mice. *Am. J. Physiol.* 1998; 274:R985–R990. [PubMed: 9575960]
- (42). Boarder, MR.; Webb, T. P2Y receptors: structure and function. In *Purinergic and Pyrimidinergic Signalling*. In: Abbracchio, MP.; Williams, M., editors. Vol. 151. *Handbook of Experimental Pharmacology*, Springer Verlag; Heidelberg: 2001. p. 65-88. Part 1
- (43). Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. *J. Biol. Chem.* 1998; 273:2030–2034. [PubMed: 9442040]
- (44). Cattaneo M. New P2Y₁₂ inhibitors. *Circulation.* 2010; 121:171–179. [PubMed: 20048234]
- (45). Ferreira, ZS.; Silva, CLM. Comparative aspects of purinergic receptors in the phylogenetic scale. *Research Signpost; Kerala, India:* 2009. p. 73-91.
- (46). Shaver SR, Rideout JL, Pendergast W, Douglass JG, Brown EG, Boyer JL, Patel RI, Redick CC, Jones AC, Picher M, Yexa BR. Structure-activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors. *Purinergic Signalling.* 2005; 1:183–191. [PubMed: 18404503]
- (47). Macfarlane DE. 2-Methylthioadenosine [32P]diphosphate: Synthesis and use as probe of platelet ADP receptors. *Methods Enzymol.* 1992; 215:137–142. [PubMed: 1435319]
- (48). Kikugawa K, Suehiro H, Ichino M. Platelet aggregation inhibitors. 6. 2-Thioadenosine derivatives. *J. Med. Chem.* 1973; 16:1381–1388. [PubMed: 4765865]
- (49). Li P, Xu Z, Liu H, Wennefors CK, Dobrikov MI, Ludwig J, Shaw BR. Synthesis of a-P-modified nucleoside diphosphates with ethylenediamine. *J. Am. Chem. Soc.* 2005; 127:16782–16783. [PubMed: 16316213]
- (50). Garrad RC, Otero MA, Erb L, Theiss PM, Clarke LL, Gonzalez FA, Turner JT, Weisman GA. Structural basis of agonist-induced desensitization and sequestration of the P2Y₂ nucleotide receptor. Consequences of truncation of the C terminus. *J. Biol. Chem.* 1998; 273:29437–29444. [PubMed: 9792648]
- (51). Brandenberger H, Hanson R. Spectrophotometric determination of acid and alkaline phosphatases. *Helv. Chim. Acta.* 1953; 36:900–906.
- (52). Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. *Semin. Thromb. Hemostasis.* 2009; 35:158–167.

- (53). Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. *Cardiovasc. Drug Rev.* 2007; 25:357–374. [PubMed: 18078435]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.
Nucleotide-based insulin secretagogue

Figure 2.
ADP(α -B) analogues tested as P2Y₁R agonists.

Scheme 1.

One-Pot Synthesis of 2-MeS-Adenosine 5'-O-(α -Borano)diphosphate, Analogue 3A^a

Figure 3.
Conformation of P-diastereomers of analogue 3.

Scheme 2.

Synthesis of 2-MeS-AP₃(-B)-A-2-MeS, Analogue 4^a

^aReaction conditions: (a) CDI (5 equiv), DMF, RT, 3 h; (b) dry MeOH (5 equiv), RT, 8 min; (c) BPi (1 equiv), DMF, MgCl₂ (8 equiv), RT, overnight.

Figure 4. Concentration-response curves for analogues 2–4 determined by measuring analogue-induced increases in $[Ca^{2+}]_i$ in human 1321N1 astrocytoma cells stably transfected with the turkey P2Y₁R.

Figure 5.
Hydrolysis of ADP, 2-MeS-ADP, and analogue 3A in human blood serum.

Figure 6.
Hydrolysis of analogue 3A at pH 1.4, 37 °C.

Figure 7.

Glucose tolerance tests in naïve mice ($n = 5$) treated with saline, analogue 3A, or glibenclamide. Fasting rats (A) and mice (B, C) were treated iv with the indicated compounds at 2.5 mg/kg (A), 10 mg/kg (B) or 30 mg/kg body weight (B, C) 10 min after glucose challenge. Glibenclamide was given orally as a positive control in (A) at 2.5 mg/kg body weight or (B) at 3 mg/kg body weight, 30 min before glucose challenge. Error bars are $\pm$ standard deviation.

Figure 8.

Glucose tolerance tests in the STZ diabetic mouse model. Diabetic (STZ) and normal (blue) mice ($n = 5$) were administered an OGTT, as described in Figure 7. Three doses of analogue 3A, 30 (purple), 15 (light blue), and 7.5 (orange) mg/kg body weight, were administered intravenously (iv) and glibenclamide (12 mg/kg body weight, green) was given PO. Saline administration to diabetic mice (red) was used as a control. Error bars are $\pm$ standard deviation.

Figure 9. Glucose tolerance tests in the db^{+}/db^{-} diabetic mouse model. The db^{+}/db^{-} mice were selected for elevated glucose levels. Analogue 3A (iv, 30 mg/kg body weight, green) and glibenclamide (PO, 20 mg/kg body weight, red) were administered with an OGTT ($n = 5$), as described in Figure 7. Error bars are $\pm$ standard deviation.

Figure 10.

Analogue 3A inhibits ADP-induced platelet aggregation in human plasma. Analogue 3A was tested for inhibition of ADP ($10 \mu\text{M}$) induced platelet aggregation in PRP obtained from one subject in duplicate samples.

Figure 11.

Anti-platelet aggregation activity of analogue 3A *in vivo*. An increase in mouse tail-bleed time was used as a model for the *in vivo* anti-platelet aggregation activity of analogue 3A in mg/kg body weight. Mice were treated iv with different doses of analogue 3A or R-361015, a compound with known anti-platelet aggregation activity, and then the tail was incised and the time to cessation of bleeding was measured. Animal numbers are above bars. Error bars are standard deviation.

Figure 12.

Oral anti-platelet aggregation activity of analogue 3A *in vivo*. Analogue 3A (30 mg/kg) or aspirin (10 mg/kg body weight) was administered PO to Lewis rats ($n = 5$) prior to tail incision, as in Figure 10. Time to cessation of bleeding (A) and total volume of exsanguinated blood (B) was measured. Error bars are $\pm$ standard deviation.

Figure 13.

Concentration-response curves for analogue 3A and ADP were determined by measuring analogue-induced increases in $[Ca^{2+}]_i$ in U-205 cells stably transfected with hP2Y₁₂R.

Table 1Chemical Shifts of Analogue 3 Isomers in D₂O

	H5''	H5'	H4'	H3'	H2'	H1'	H8
3A <i>R_p</i> -isomer	4.00	4.12	4.24	4.47	4.60	5.99	8.45
3B <i>S_p</i> -isomer	4.00	4.12	4.25	4.39	4.62	5.99	8.42

Table 2

Enzymatic Stability at 37 °C of Analogues 2–4

analogue	% hydrolysis of human eNPP1	$t_{1/2}$ (h)	
		human blood serum	alkaline phosphatase
ADP	25	2	4
2-MeS-ADP	16	23	4.5
analogue 2, A isomer	5	3.5	4.2
analogue 3, A isomer	4	>24	6
analogue 4, A isomer	0	14	<i>a</i>
analogue 4, B isomer	5	14	<i>a</i>

^a Not hydrolyzed.